Literature DB >> 19853970

[The treatment of arterial hypertension: evidence of efficacy and conclusions that may be drawn].

Jordi Vilaseca Canals, Jordi Espinàs Boquet, Eduard Diogène Fadini, Dolors Rodríguez Cumplido, Carmen Asensio Ostos, Carlos Fluixá Carrascosa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19853970      PMCID： PMC7022100          DOI： 10.1016/j.aprim.2009.09.012

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  7 in total

1.  [semFYC therapeutic guidelines in primary care. Essential Arterial Hypertension Section: Updated? Evidence based?].

Authors:  José Abellán Alemán; Mariano Leal Hernández; Antonio Martínez Pastor; José García-Galbis Marín
Journal:  Aten Primaria       Date:  2009-03-21       Impact factor: 1.137

2.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

3.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Joshua I Barzilay; Barry R Davis; Jeffrey A Cutler; Sara L Pressel; Paul K Whelton; Jan Basile; Karen L Margolis; Stephen T Ong; Laurie S Sadler; John Summerson
Journal:  Arch Intern Med       Date:  2006-11-13

4.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

Review 5.  Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Authors:  David B Matchar; Douglas C McCrory; Lori A Orlando; Manesh R Patel; Uptal D Patel; Meenal B Patwardhan; Benjamin Powers; Gregory P Samsa; Rebecca N Gray
Journal:  Ann Intern Med       Date:  2007-11-05       Impact factor: 25.391

6.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

Review 7.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321
  7 in total
  1 in total

1.  [High blood pressure: beyond the guidelines].

Authors:  Josep Serra Tarragón
Journal:  Aten Primaria       Date:  2010-03-31       Impact factor: 1.137
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.